Show simple item record

Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT) .

dc.contributor.authorChaparro, M
dc.contributor.authorGarcía Donday, M
dc.contributor.authorRiestra, S
dc.contributor.authorVan Domselaar, M.
dc.contributor.authorGisbert, J P
dc.date.accessioned2024-02-22T12:03:08Z
dc.date.available2024-02-22T12:03:08Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/10641/4075
dc.language.isoengspa
dc.publisherJournal of Crohn's and Colitisspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleIs the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT) .spa
dc.typeotherspa
dc.type.hasVersionAMspa
dc.rights.accessRightsopen accessspa
dc.description.extent6877 KBspa
dc.identifier.doi10.1093/ecco-jcc/jjac190.0037spa


Files in this item

FilesSizeFormatView
jjac190.0037222.pdf6.715MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España